Overview

Trial of Hydroxychloroquine In Covid-19 Kinetics

Status:
Terminated
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by PCR) , 7 days after initiation of therapy compared to control patients receiving placebo. The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial initiated immediately after diagnosis in ambulatory health care workers at University of South Alabama Health, or in ambulatory USA patients. At 7 days after enrollment another nasopharyngeal swab will be taken to measure if the virus is still present. At 10 weeks we will measure immunity from Covid-19 using a single blood sample. It is a phase 2/3 clinical trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of South Alabama
Treatments:
Hydroxychloroquine